Clinical Trials Act 2011

Section 10: Functions of Pharmacovigilance Committee

PART IV: PHARMACOVIGILANCE COMMITTEE

Clinical Trials Act 2011Section 10

10. Functions of Pharmacovigilance Committee (1) The functions of the Pharmacovigilance Committee shall be to – (a) collect all available information on adverse events and adverse reactions, in Mauritius or elsewhere, particularly in relation to subjects involved in clinical trials; (b) analyse and classify any such information and communicate it to the health personnel and to the public and, where appropriate, to the relevant division of the World Health Organisation; (c) liaise with the Trade and Therapeutics Committee for the purpose of recommending measures, by means of legislation or otherwise, to minimise the risk of adverse events and adverse reactions; 104 Acts 2011 (d) ensure that health personnel are given adequate training in the collection and analysis of adverse events and adverse reactions; (e) depute any of its members, where it deems necessary, to conduct an inspection in accordance with section 26; (f) advise the Council and the Ethics Committee on any matter specified in this section. (2) The Pharmacovigilance Committee shall establish and follow its own standard operating procedures. PART V – TRIAL LICENCE

Start date not held: comes into operation on a date fixed by Proclamation, and juris holds no Proclamation for it.

as enacted (not consolidated). juris shows this Act from a copy that is not the official consolidation, so it may not carry every amendment; the amendments juris holds are listed. It does not confirm that this is the law in force today.

Ask juris about this section Official source